Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy

Thomas A. Faunce, Evan Doran, David Henry, Peter Drahos, Andrew Searles, Brita Pekarsky, Warwick Neville

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)

Abstract

On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts - if any - the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent an important precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also be of great interest to policy makers in other jurisdictions.

Original languageEnglish
Article number15
JournalGlobalization and Health
Volume1
DOIs
Publication statusPublished - 6 Oct 2005
Externally publishedYes

Fingerprint

Administrative Personnel
Cost-Benefit Analysis
Pharmaceutical Preparations
Intellectual Property
Pharmaceutical Economics
Federal Government
Public Policy
Health Policy
Industry
Public Health
Research Personnel
Costs and Cost Analysis
Research

Cite this

Faunce, Thomas A. ; Doran, Evan ; Henry, David ; Drahos, Peter ; Searles, Andrew ; Pekarsky, Brita ; Neville, Warwick. / Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. In: Globalization and Health. 2005 ; Vol. 1.
@article{bde5bf940e564e77952de9d118343a39,
title = "Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy",
abstract = "On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts - if any - the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent an important precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also be of great interest to policy makers in other jurisdictions.",
author = "Faunce, {Thomas A.} and Evan Doran and David Henry and Peter Drahos and Andrew Searles and Brita Pekarsky and Warwick Neville",
year = "2005",
month = "10",
day = "6",
doi = "10.1186/1744-8603-1-15",
language = "English",
volume = "1",
journal = "Globalization and Health",
issn = "1744-8603",
publisher = "BioMed Central",

}

Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. / Faunce, Thomas A.; Doran, Evan; Henry, David; Drahos, Peter; Searles, Andrew; Pekarsky, Brita; Neville, Warwick.

In: Globalization and Health, Vol. 1, 15, 06.10.2005.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy

AU - Faunce, Thomas A.

AU - Doran, Evan

AU - Henry, David

AU - Drahos, Peter

AU - Searles, Andrew

AU - Pekarsky, Brita

AU - Neville, Warwick

PY - 2005/10/6

Y1 - 2005/10/6

N2 - On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts - if any - the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent an important precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also be of great interest to policy makers in other jurisdictions.

AB - On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts - if any - the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent an important precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also be of great interest to policy makers in other jurisdictions.

UR - http://www.scopus.com/inward/record.url?scp=29444443468&partnerID=8YFLogxK

U2 - 10.1186/1744-8603-1-15

DO - 10.1186/1744-8603-1-15

M3 - Article

VL - 1

JO - Globalization and Health

JF - Globalization and Health

SN - 1744-8603

M1 - 15

ER -